Preliminary results of a dose-finding study of PTK787/ZK222584 (PTK/ZK) in combination with weekly vinorelbine (V) and trastuzumab (T) as treatment of patients (pts) with metastatic breast cancer (MBC) overexpressing HER-2/neu, previously treated with at least one line of chemotherapy (CT)